^
    4ms
    Cisplatin Disposition and Kidney Injury (clinicaltrials.gov)
    P3, N=72, Active, not recruiting, University of Colorado, Denver | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Sep 2025 --> Sep 2027
    Trial completion date • Trial primary completion date
    |
    cisplatin • granisetron oral • ondansetron • palonosetron intravenous
    1year
    Oral Akynzeo® Vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk) (clinicaltrials.gov)
    P4, N=414, Completed, Helsinn Healthcare SA | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Jul 2024
    Trial completion • Trial completion date
    |
    Akynzeo oral (netupitant/palonesteron FDC) • granisetron oral • ondansetron intravenous
    over1year
    Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk) (clinicaltrials.gov)
    P4, N=414, Active, not recruiting, Helsinn Healthcare SA | Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2024 --> Jul 2024
    Enrollment closed • Trial primary completion date
    |
    Akynzeo oral (netupitant/palonesteron FDC) • granisetron oral • ondansetron intravenous
    almost2years
    Granisetron Versus Ondansetron for Nausea and Vomiting in Pediatric Age Group (clinicaltrials.gov)
    P=N/A, N=160, Completed, Ain Shams University
    New trial
    |
    Zuplenz (ondansetron oral dispersible film) • granisetron oral
    2years
    Cisplatin Disposition and Kidney Injury (clinicaltrials.gov)
    P3, N=72, Recruiting, University of Colorado, Denver | Phase classification: P=N/A --> P3 | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Sep 2023 --> Sep 2025
    Phase classification • Trial completion date • Trial primary completion date
    |
    cisplatin • granisetron oral • ondansetron • palonosetron intravenous
    over4years
    [VIRTUAL] Phase II Trial of Antiemetic Oral Granisetron Plus Dexamethasone for Nausea and Vomiting Caused by Crizotinib in ALK or ROS1 Fusion - Positive NSCLC (IASLC-WCLC 2021)
    Conclusion The double combination of oral granisetron plus dexamethasone is the valid prophylactic regimen for nausea and vomiting caused by crizotinib in patients with ALK or ROS1-positive NSCLC. Clinical trial information: jRCTs031180378.
    P2 data
    |
    ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK positive • MET exon 14 mutation • ALK fusion • ROS1 fusion • ROS1 positive • ALK-ROS1 fusion
    |
    Xalkori (crizotinib) • dexamethasone • granisetron oral